Webcast ImageWebcast
Fostamatinib Phase 3 Results for Second ITP Trial - Conference Call (Replay)
October 20, 2016 at 8:00 a.m. ET

Corporate Profile

Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from two Phase 3 clinical studies in chronic immune thrombocytopenia, or ITP, in August and October 2016. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Recent News

More »
10/20/16Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP
Conference call and webcast today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Oct. 20, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced results for the second of two double-blind studies in the FIT Phase 3 clinical program for fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in adult chronic/persistent immune thrombocytopenia (ITP).  The primary endpoint in the study was a stable platelet response, defined as platelet counts greater than 5... 
Printer Friendly Version
10/07/16Rigel Expands Leadership Team in Research and Business Development
Reaffirms research focus and IRAK program plans SOUTH SAN FRANICSCO, Calif., Oct. 7, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced the appointment of two company veterans to leadership roles that will impact Rigel's newly refocused small molecule R&D effort targeting immunology and oncology diseases.  Esteban Masuda, Ph.D., who has made significant contributions to Rigel's research programs for 18 years, has been named Senior Vice President, Research. Joseph ... 
Printer Friendly Version
09/15/16Rigel Restructures to Focus on Fostamatinib Commercialization
Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced plans to build a commercial organization to support the potential launch of fostamatinib, its oral SYK inhibitor, for the treatment of chronic immune thrombocytopenia (ITP). The company recently reported that fostamatinib met the primary endpoint in the first of two identical Phase 3 studies in chro... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) - 0.11 (4.09%)
Data as of 10/26/16 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $2.58 with a 52 week high of $4.38 and a 52 week low of $1.88.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.